Stock NSTM NOVELSTEM INTERNATIONAL CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials NovelStem International Corp.

Equities

NSTM

US67001V1098

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 17:07:06 24/04/2024 BST 		5-day change 1st Jan Change
0.06 USD -.--% Intraday chart for NovelStem International Corp. -.--% -4.61%
04-01 NovelStem International Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 NovelStem International Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 7.076 13.13 8.804 2.949
Enterprise Value (EV) 1 6.987 13.22 9.086 6.47
P/E ratio -16.1 x -25.8 x -9.39 x -0.7 x
Yield - - - -
Capitalization / Revenue - - 733,695,083 x 245,737,000 x
EV / Revenue - - 757,203,750 x 539,198,333 x
EV / EBITDA - - - -
EV / FCF - -955,551,724 x -38,737,099 x -55,457,389 x
FCF Yield - -0% -0% -0%
Price to Book 2.33 x 3.96 x 4.56 x -1.51 x
Nbr of stocks (in thousands) 35,381 46,881 46,881 46,881
Reference price 2 0.2000 0.2800 0.1878 0.0629
Announcement Date 02/08/22 02/08/22 01/04/24 01/04/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales - - 0.012 0.012
EBITDA - - - -
EBIT 1 -0.2303 -0.4955 -0.7324 -0.6533
Operating Margin - - -6,103.62% -5,443.98%
Earnings before Tax (EBT) 1 -0.51 -0.4811 -0.7657 -4.187
Net income 1 -0.51 -0.4811 -0.7657 -4.187
Net margin - - -6,381.08% -34,894.17%
EPS 2 -0.0124 -0.0109 -0.0200 -0.0900
Free Cash Flow - -0.0138 -0.2346 -0.1167
FCF margin - - -1,954.72% -972.28%
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 02/08/22 02/08/22 01/04/24 01/04/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 - 0.09 0.28 3.52
Net Cash position 1 0.09 - - -
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - -0.01 -0.23 -0.12
ROE (net income / shareholders' equity) - -14.1% -35.2% 44,894%
ROA (Net income/ Total Assets) - -8.72% -18.7% -18%
Assets 1 - 5.516 4.094 23.28
Book Value Per Share 2 0.0900 0.0700 0.0400 -0.0400
Cash Flow per Share 2 0 0 0 0
Capex - - - -
Capex / Sales - - - -
Announcement Date 02/08/22 02/08/22 01/04/24 01/04/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
NOVELSTEM INTERNATIONAL CORP. Stock NovelStem International Corp.
-4.61% 2.81M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+5.66% 109B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.23% 105B
ARGENX SE Stock argenx SE
-0.38% 22.25B
BIONTECH SE Stock BioNTech SE
-12.15% 22.09B
GENMAB A/S Stock Genmab A/S
-7.66% 18.68B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-36.52% 17.58B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.09% 16.85B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.33% 13.76B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.58% 12.46B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. NSTM Stock
  4. Financials NovelStem International Corp.